Method for Producing Cardiomyocytes by Means of Reprogramming
AssigneesPlastech Pharmaceutical Technology Co., Ltd., Peking University
InventorsYang Zhao, Yanmeng Tao, Jingdong Wu, Hao Wang
Life of this patent
Estimating the term…
Abstract
The present invention relates to the field of biomedicine, in particular regenerative medicine. In particular, the present invention relates to a method for producing cardiomyocytes from differentiated cells, such as fibroblasts, by means of reprogramming using a Tyk2 inhibitor and/or a TGFβ inhibitor, and optionally a cardiomyocyte-inducing transcription factor.
Claims31
A method for reprogramming a starting cell into a cardiomyocyte, the method comprising contacting the starting cell with at least one Tyk2 inhibitor and/or at least one TGFβ inhibitor.
A method for treating a cardiac disease in a subject, the method comprising administering to the subject at least one Tyk2 inhibitor and/or at least one TGFβ inhibitor.
Dependencies are inferred from the claim text.